Insider Selling: Teladoc Health (NYSE:TDOC) Insider Sells $270,774.40 in Stock

Key Points

• Insider Carlos Nueno sold 29,432 Teladoc shares for $270,774.40 at an average price of $9.20 under a pre-arranged Rule 10b5-1 plan. He retained 35,312 shares after the sale.
• Teladoc reported quarterly EPS of -$0.15, beating the -$0.22 consensus, and revenue of $605.1 million, above expectations; revenue nevertheless fell 3.4% year over year.
• Analysts’ consensus rating was Hold, with an average price target of $8.53; five analysts rated the stock Buy, 12 Hold, and two Sell.

Teladoc Health, Inc. (NYSE:TDOC - Get Free Report) insider Carlos Nueno sold 29,432 shares of Teladoc Health stock in a transaction that occurred on Friday, November 6th. The shares were sold at an average price of $9.20, for a total value of $270,774.40. Following the sale, the insider directly owned 35,312 shares in the company, valued at approximately $324,870.40. This trade represents a 45.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Teladoc Health Price Performance

Shares of NYSE TDOC traded up $0.23 during midday trading on Monday, hitting $9.01. 4,029,957 shares of the company's stock were exchanged, compared to its average volume of 5,153,952. The stock's 50 day moving average price is $6.51 and its 200-day moving average price is $6.54. The firm has a market cap of $1.64 billion, a P/E ratio of -10.47 and a beta of 2.00. Teladoc Health, Inc. has a twelve month low of $4.40 and a twelve month high of $9.89.

Teladoc Health (NYSE:TDOC - Get Free Report) last posted its earnings results on Wednesday, October 28th. The health services provider reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.07. The firm had revenue of $605.10 million for the quarter, compared to analysts' expectations of $588.14 million. Teladoc Health had a negative return on equity of 11.63% and a negative net margin of 6.27%. The firm's revenue was down 3.4% compared to the same quarter last year. During the same period last year, the firm earned ($0.28) EPS. On average, analysts expect that Teladoc Health, Inc. will post -0.86 EPS for the current fiscal year.

Institutional Trading of Teladoc Health

Institutional investors have recently bought and sold shares of the company. Formidable Asset Management LLC increased its position in Teladoc Health by 6.2% in the 3rd quarter. Formidable Asset Management LLC now owns 27,935 shares of the health services provider's stock worth $162,000 after purchasing an additional 1,625 shares during the last quarter. Versant Capital Management Inc lifted its holdings in shares of Teladoc Health by 33.3% during the 2nd quarter. Versant Capital Management Inc now owns 8,207 shares of the health services provider's stock valued at $70,000 after buying an additional 2,052 shares during the last quarter. Allworth Financial LP grew its stake in shares of Teladoc Health by 78.9% in the 3rd quarter. Allworth Financial LP now owns 5,255 shares of the health services provider's stock valued at $30,000 after buying an additional 2,317 shares in the last quarter. Robeco Institutional Asset Management B.V. grew its stake in shares of Teladoc Health by 9.5% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 29,722 shares of the health services provider's stock valued at $172,000 after buying an additional 2,578 shares in the last quarter. Finally, HighTower Advisors LLC grew its stake in shares of Teladoc Health by 20.8% in the 2nd quarter. HighTower Advisors LLC now owns 16,808 shares of the health services provider's stock valued at $143,000 after buying an additional 2,893 shares in the last quarter. Institutional investors and hedge funds own 76.82% of the company's stock.

Analyst Ratings Changes

TDOC has been the subject of a number of research reports. Barclays raised their price objective on Teladoc Health from $7.00 to $9.00 and gave the stock an "equal weight" rating in a research report on Wednesday, November 4th. Oppenheimer raised their price target on shares of Teladoc Health from $7.00 to $10.00 and gave the stock an "outperform" rating in a report on Monday, November 2nd. Weiss Ratings restated a "sell (d-)" rating on shares of Teladoc Health in a report on Wednesday, August 19th. Argus downgraded shares of Teladoc Health from a "hold" rating to a "sell" rating in a research report on Monday, November 2nd. Finally, Wells Fargo & Company upped their price objective on shares of Teladoc Health from $6.00 to $8.00 and gave the company an "equal weight" rating in a research note on Thursday. Five research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $8.53.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services and technology designed to connect patients with medical professionals remotely. Through its digital platforms, the company supports a range of healthcare needs, including general medical consultations, mental health services, specialty care, and ongoing management of chronic conditions.

Its offerings include telehealth visits with physicians and other licensed providers, behavioral health services through BetterHelp, and chronic care programs that use digital tools and clinical support to help people manage conditions such as diabetes and hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.